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1. Introduction {#sec0005}
===============

The rat sarcoma viral oncogene homolog (RAS) family of membrane associated GTPase signalling molecules are involved in pathways that mediate cell growth. Many of these pathways interact, and different cell types use them differently, so the effects of activation by growth factors or mutation in key genes differ between cell and cancer types. The human RAS family consists of three genes Harvey RAS (*HRAS*), Kirsten RAS (*KRAS*), and Neuroblastoma RAS (*NRAS*) [@bib0005], [@bib0010].

The clinical need for *KRAS* mutation testing is largely related to the use of anti-EGFR antibody therapy for patients with advanced colorectal cancer [@bib0015]. Virtually all colorectal cancers express EGFR, but few respond to treatment directed against the receptor because they have downstream activating mutations in signalling molecules including KRAS. It has now been shown that *NRAS* mutations in patients with colorectal cancer have the same effect. There is also increasing evidence from systematic reviews that B-Raf proto-oncogene (*BRAF*) mutations, which confer a worse prognosis, also confer a degree of resistance [@bib0020], and strong suspicion that *PIK3CA* mutations are also important [@bib0020]. This backs up reports from series of patients treated with anti-EGFR molecules [@bib0025], and in vitro data using cell lines, in which activation of downstream signalling leads to resistance to anti-EGFR molecules [@bib0030]. It also has recently become apparent that resistance may occur during treatment due to new mutations in *EGFR*, *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* genes [@bib0035]. While the pharmaceutical licenses for anti-EGFR antibody therapeutics (e.g. cetuximab, panitumumab) granted by the Federal Drug Administration, and in the Europe by the European Medicines Agency (EMA), require the use of *KRAS* and *NRAS* mutation testing to exclude mutations before their use, this is not yet a requirement for *BRAF* or *PIK3CA* [@bib0040], [@bib0045].

KRAS is of importance in other tumour types, and knowledge of *KRAS* mutational status can be helpful to guide further investigations. For instance, if a lung cancer has a *KRAS* mutation, there is little point in sending off biopsy material for Anaplastic lymphoma kinase (*ALK*) fusion gene testing, as the *KRAS* mutation will be the driver mutation and *ALK* will almost certainly be wild-type [@bib0050]. As yet, there are few therapeutic options for patients with *KRAS* mutated tumours, but this is likely to change, and knowledge of the *KRAS* mutational status of many tumours will then be of greater significance [@bib0040].

The activation of molecules such as *KRAS* by mutation requires conformational changes at the protein level, so not all mutations in *KRAS* are activating and able to drive carcinogenesis [@bib0005], [@bib0045]. There are therefore 'hotspots' within *KRAS* that allow testing to be done without sequencing the entire gene. The American Society of Clinical Oncology (ASCO) have recently published guidance recommending testing of codons 12 and 13 of exon 2; 59 and 61 of exon 3; and 117 and 146 of exon 4 (known as "expanded" or "extended" RAS mutation testing, [Table 1](#tbl0005){ref-type="table"}) [@bib0045]. This list is now widely used, but not all commercially available tests cover these codons. The corresponding mutations covered in guidance for testing laboratories are listed in [Table 1](#tbl0005){ref-type="table"}, with example mutations. Most external quality assurance (EQA) schemes (e.g. UKNEQAS, Edinburgh, UK and European Society of Pathology EQA scheme) require reports to be submitted to their molecular pathology schemes, based on drug licence information (see <http://www.ukneqas-molgen.org.uk/molecular-pathology> and <http://kras.eqascheme.org>) [@bib0055], [@bib0060].

2. PCR tests for *KRAS* mutation {#sec0010}
================================

Tests for *KRAS* mutations usually employ polymerase chain reaction (PCR). Modern, particularly automated, PCR methods are relatively simple to perform and provide rapid diagnosis at good sensitivity. It is perfectly possible to go from formalin-fixed paraffin-embedded (FFPE) tumour sample to result in a few hours, rather than a few days. There are a large number of methods available, suited to small and large laboratories. Most manufacturers of PCR machines used clinically have options for RAS analysis. The commonest commercial options are well validated, widely used, and as shown in [Table 2](#tbl0010){ref-type="table"}, in three cases, approved by the US Federal Drug Administration (FDA). The Therascreen (Qiagen) offering is based on the amplification refractory mutation system (ARMS) technology [@bib0065], [@bib0070], and is widely used. The Cobas (Roche) assay uses a CE-IVD marked TaqMelt PCR assay designed to detect the presence of 19 *KRAS* mutations in codons 12, 13, and 61 from just 100 ng of DNA extracted from FFPE samples [@bib0075]. Comparison the two assays have shown excellent concordance [@bib0080], but it should be noted that the cobas assay has a more extensive coverage. The most recently approved assay, the Idylla system from Biocartis, integrates DNA extraction and multiplex PCR in a simple-to-use cassette, and also has wide coverage ([www.biocartis.com](http://www.biocartis.com){#intr0020}). There are presently few publications using this method, but its first offering for BRAF mutation has performed well [@bib0085], [@bib0090], [@bib0095].

The limit of detection (LoD) is given by most manufacturers as the lowest percentage mutant DNA detectable against background wild-type DNA. The best assays achieve 1%, but most manufacturers quote \<5% in their literature. This means that the lower the percentage of neoplastic cells present, the higher the effective limit of detection. Manufacturers and users generally quote 10% neoplastic cells as a threshold below which it is not worth testing, as the effective limit of detection for mutations in such clinical material will be between 10% and 50% at that point [@bib0055]. It is important that this is taken into account when reporting the results of such tests, and close cooperation between histopathology and molecular pathology is essential [@bib0055].

Laboratory-developed tests (also known as in-house assays) for RAS mutation analysis ([Table 3](#tbl0015){ref-type="table"}) are widely used in Europe and by clinical laboratories operating under the The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations in the USA, as well as in research. The onus is on the laboratory to validate the test to ensure that the results are reliable [@bib0055]. Many of reagents are sold as research use only (RUO). The results from external quality assurance schemes (e.g. UKNEQAS, ESP) suggest that in well-run, suitably accredited laboratories, such tests are as safe and effective as those with approval for clinical use [@bib0055].

One advantage of developing tests locally is that there are a large number of different methods to choose from and it is possible to design tests to meet local requirements. Most methods use some of PCR enrichment to ensure low levels of detection of mutant DNA against a background of wild-type DNA. The castPCR (ThermoFisher) method can be used in both 96 well plates and TaqMan Arrays and shows good concordance with both Therascreen (Qiagen) and IonTorrent NGS [@bib0100], [@bib0105]. PCR clamping incorporates peptide nucleic acids (PNAs) or locked nucleic acids (LNAs) to reduce the amplification of mutant DNA [@bib0110], [@bib0115], [@bib0120], [@bib0125], while high resolution melt (HRM) methods use close control of annealing temperatures to favour amplification of mutant DNA[@bib0130], [@bib0135]. HRM can also be used as a prior to sequencing to increase sensitivity [@bib0140], [@bib0145].

3. Factors affecting assay choice {#sec0015}
=================================

Guidance for molecular pathology [@bib0055] covers most of the requirements for test implementation and should be consulted before starting. One of the key considerations for assay choice is the number of samples needing testing. There is a trade-off between the cost per assay and the number performed. Efficiencies of scale mean that for many laboratories, it is better to send away rarely required tests, and to concentrate on those that are commonly requested. Turnaround time for patients, from biopsy to action on the result of a test, tends to be slower for those samples sent away, and if the result is required quickly, this may mean that a laboratory has to take on testing it would otherwise prefer to send away. Timeliness of diagnostic reporting is an essential component of the decision, and should be considered by multidisciplinary teams (tumour boards) considering setting up such services.

Laboratory facilities are a further consideration. Space is rarely an issue as PCR machines are all of bench-top type, but most molecular pathology methods require considerable expertise both to extract DNA from samples, to perform the tests, and to interpret the results.

Both NGS and PCR have advantages and disadvantages. While sequencing can look at entire genes, most PCR methods and targeted sequencing methods employ primers and probes that look for defined mutations. This makes them less comprehensive, but makes interpretation easier. Many next targeted generation sequencing (NGS) depend on PCR for library preparation and some can be thought of as a post-PCR methods (e.g. IonTorrent Ampliseq, ThermoFisher, Paisley, UK) [@bib0150], [@bib0155]. Targeted NGS uses the application of highly parallel sequencing methods to analyse vast numbers of overlapping PCR products to cover whole exons or even genes. This allows even rare mutations to be detected, but at a cost in terms of time, complexity of analysis and interpretation, and economics [@bib0055].

Whatever the analytical method used, DNA needs to be extracted from formalin-fixed, paraffin-embedded (FFPE) tissue for assay. It is important to ensure that tissue is fixed promptly, but not overfixed (i.e. \<72 h), and that neutral buffered formalin is used [@bib0055]. Tissue processing should not use high temperatures (i.e. \<65 °C) to optimise DNA recovery [@bib0160]. DNA extraction can be manual, using one of several systems from companies such as ClonTech, ThermoFisher and Qiagen, or automated. We have used the Maxwell (Promega) system for a number of years, with good results, but other systems are coming onto the market, several of which use standard laboratory robots [@bib0100], [@bib0160]. One difference is that while all automated systems tend to use enzymatic release and magnetic bead based extraction, manual systems are often filter-based. DNA can also be released from FFPE by focussed ultrasound (Covaris, <http://covarisinc.com/products/ffpe-extraction/>), a method that has found application in the extraction of DNA for sequencing [@bib0165]. Completely automated cassette-based systems, which do their own extraction, are a rarity, but the Idylla (Biocartis) is an example [@bib0085], [@bib0090], [@bib0095].

Commercial assays are designed to cope with the demands of mutation detection in the fragmented DNA recovered from FFPE samples. Most of the DNA recovered will be less than 150 base pairs in length, and this is therefore the maximum length of the PCR products that should be used in *KRAS* and other gene mutation assays [@bib0055]. Shorter amplicon sizes can improve sensitivity. The same issue applies to NGS, and causes problems for whole genome sequencing in particular. The alternative is to use fresh tissue, but that may compromise the histopathological diagnosis and is not recommended. The histopathologist should assess the sample, estimate the percentage of neoplastic cells present, and mark areas for assay. Many laboratories use sections scraped from glass slides, while others use rolled sections. For larger biopsies or surgical resections, we use disposable 1 mm punches to take a core from the block corresponding to areas of tumour with \>50% neoplastic cells marked on the diagnostic H&E slide [@bib0100].

Interpretation of the results of *KRAS* mutation analysis, or indeed any other molecular assay, requires knowledge of the assay, and the pre-analytical issues, but also an appreciation of the likely clinical consequences of the results and the drugs used. In Europe, the pathologist signing the report is responsible for its accuracy, even if the assay is performed in another laboratory. The ease with which results can be assessed and reported varies between systems, and few interface directly with Laboratory Information Management Systems (LIMS). In this respect, PCR and sequencing technologies lag behind those used in automated blood sciences labs, or histopathology. The consequence is that results need to be typed into LIMS systems manually, with the inherent risks of sample misidentification and typographical errors in mutations. Mutations should be reported using Human Genome Variation Society (HGVS) nomenclature (<http://www.hgvs.org/mutnomen/>) and an interpretation given which is understandable to the clinician who must act on it, while allowing a pathologist to understand what test has been done and its limitations.

The effect of all of these choices on service provision can be modelled using the Cancer Molecular Diagnostic Implementation Planning and Commissioning Toolkit

(CMD-ImPACT) tool which is freely available from the UK Royal College of Pathologists (RCPath) website ([https://www.rcpath.org/cmd-impact.html](http://https://www.rcpath.org/cmd-impact.html){#intr0035}). Guidance on how to set up and run a molecular pathology laboratory is available from several sources, particularly College of American Pathologists (<http://www.cap.org/>), the Association for Molecular Pathology (<http://www.amp.org>), and the European Society of Pathology [@bib0055].

4. Future directions {#sec0020}
====================

There is little doubt that more drugs will become available, and the need for KRAS testing will increase. However, the number of targets requiring interrogation is also increasing, and KRAS is but one of these. There is therefore an increasing requirement to test more than one gene in a given cancer, and the use of panel testing is likely to increase accordingly. Sequencing panels such as the IonTorrent colorectal and lung cancer 22 gene panel are comprehensive, but NGS requires considerable expertise and remains more expensive than PCR. We have recently developed an in-house Taqman array panel for commonly requested mutations in RAS (KRAS and NRAS), EGFR, and BRAF [@bib0105]. We are able to extract DNA from 7 samples and run the plate within a few hours with around 15 min hands-on time, allowing us to run a plate twice week giving patients a maximum turnaround time of 3--4 days. Those samples in which no mutation is found, or where there is a clinical requirement for additional information, can then submitted for further testing by NGS or FISH.

Finally, the use of liquid biopsy is rapidly increasing, and has entered practice in some centres to augment tissue based testing [@bib0170]. Circulating free DNA (cfDNA) should be extracted from plasma rather than serum. Although cfDNA levels in serum are higher, this reflects DNA from leukocytes due to clotting, and there is consequent dilution of circulating tumour-derived DNA (ctDNA). Plasma cfDNA is fragmented and product sizes less than 150 bp are required. Methods with greatest sensitivity include BEAMing and digital droplet PCR, but IonTorrent sequencing is also able to reach similar sensitivity (Laurent-Puig, personal communication). A number of new assays are in development and this field is developing rapidly. To date, there have been insufficient clinical validation studies reported. These are a requirement if these methods are to be used in the clinic, where they could certainly meet a need for patients on treatment who require monitoring, and in patients where biopsy material is not available.
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###### 

Mutations in *KRAS* and *NRAS* for which testing should be performed in patients with colorectal cancer. The exons and codons listed are common to both *KRAS* and *NRAS*.

Table 1

  Exon   Codon   Example Mutations
  ------ ------- ---------------------
  2      12      G12C (c.34G \> T)
                 G12R (c.34G \> C)
                 G12S (c.34G \> A)
                 G12A (c.35G \> C)
                 G12D (c.35G \> A)
                 G12V (c.35G \> T)
         13      G13D (c.38G \> A)
  3      59      A59E (c.176C \> A)
                 A59G (c.176C \> G)
                 A59T (c.175G \> A)
         61      Q61K (c.181C \> A)
                 Q61L (c.182A \> T)
                 Q61R (c.182A \> G)
                 Q61H (c.183A \> C)
                 Q61H (c.183A \> T)
  4      117     K117N (c.351A \> C)
         146     A146P (c.436G \> C)
                 A146T (c.436G \> A)
                 A146V (c.437C \> T)

###### 

Currently available PCR methods (FDA approved) for FFPE tissue determination of *KRAS* mutation status. LoD, Limit of Detection <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm>.

Table 2

  Features                       Therascreen (Qiagen)   Cobas (Roche)       Idylla (Biocartis)
  ------------------------------ ---------------------- ------------------- ---------------------------------
  Starting material              DNA                    DNA                 FFPE section
  Coverage                       Codons 12 and 13       Codons 12, 13, 61   Codons 12, 13, 59, 61, 117, 146
  Analytical Sensitivity (LoD)   \<5%                   \<5%                5%
  Neoplastic cell% limit         10%                    10%                 NA
  Duration of test               \<8 h                  \<8 h               2 h
  Reagents                       Liquid                 Liquid              Cassette
  Results                        Manual                 Automated           Automated

###### 

Examples of currently available PCR methods using RUO reagents.

Table 3

  -----------------------------------------------------------------------------------------------------------------------------
  Features                       CastPCR (ThermoFisher)                       PCR Clamping          High Resolution Melt
  ------------------------------ -------------------------------------------- --------------------- ---------------------------
  Starting material              DNA                                          DNA                   DNA

  Coverage                       Depends on plate layout                      Depends on primers\   Depends on primers chosen
                                                                              chosen                

  Analytical Sensitivity (LoD)   \<5%                                         \<5%                  \<5%

  Neoplastic cell% limit         10%                                          10%                   10%

  Duration of test               3 h                                          3--4 h                3--4 h

  Reagents                       Lyophilised in plate + master mix (liquid)   Liquid                Liquid

  Results                        Manual                                       Manual                Manual
  -----------------------------------------------------------------------------------------------------------------------------
